WILEX AG receives preliminary results of the phase III trial with the diagnostic REDECTANE®

Munich, 29 November 2009 - The biopharmaceutical company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) was informed by the external clinical research organisation (CRO) that the results of the preliminary data of the phase III trial with REDECTANE® expected at the end of December have now been completed earlier than anticipated.

The aim of the Phase III-REDECT study was to determine whether the combination of REDECTANE® with positron emission tomography (PET) and computer tomography (CT) versus the standard use of CT alone could improve the diagnosis of renal masses. Sensitivity and specificity were the defined endpoints of the study. In order to avoid unnecessary surgery of renal masses in future a diagnostic agent should predict that clear cell renal cell cancer is not present (specificity).

The results of the study demonstrate that PET/CT with REDECTANE® lead to an improved diagnosis in comparison to CT. The study endpoint specificity, the correct diagnosis that clear cell renal cell cancer is not present, was achieved with a highly statistical value (p value, p) (p<0.001). The second endpoint, the correct diagnosis of clear cell renal cell cancer (sensitivity), just failed to achieve statistical significance (p=0.052 instead of p<0.050). CT performed better with respect to sensitivity in the study than expected and than generally observed in clinical practise. The final patient data is still to be analysed. Small changes can significantly impact the statistical results.

WILEX expects the final results in the first quarter 2010 and plans to discuss these with external experts and to consult the process going forward with the US Food and Drug Administration (FDA).

Dr. Paul Bevan, Head of R&D and member of the executive management board commented: „The preliminary data support our hypothesis that PET/CT with REDECTANE® is superior to CT alone in the diagnosis of clear cell renal cell cancer. We are especially surprised at the superiority of REDECTANE® to CT in the diagnosis that clear cell renal cell cancer is not present. This could avoid unnecessary surgery of renal masses in future“.

Invitation to a conference call
On 30 November 2009, WILEX will hold a conference call for media representatives, analysts and investors in English at 3:00 p.m. CET. Please dial in ten minutes before the conference call using the following dial-in numbers:

1. Germany: +49 (0)89 2040 3812
2. UK: +44 (0)207 0980 693
3. USA: +1 703 621 9129

When asked, please enter the PIN code 400404# and clearly state your name and company. The presentation for the conference (in English) will be available for download at www.wilex.com from 2:30 p.m. CET.

Important notes
This press release does not constitute either an offer to sell or an invitation to buy securities. In particular, this document does not constitute an offer to sell securities or a solicitation of an offer to buy securities in the United States of America. The shares of WILEX AG (the "Shares") may not be offered or sold in the United States of America or to or for the account or benefit of "U.S. persons" (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")), unless they have been registered or are exempt from registration under the Securities Act. The Shares have not been and will not be registered under the Securities Act. There will be no public offer of Shares in the United States of America.

Contact
Katja Arnold (CIRO)
WILEX AG
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors@wilex.com

Additional media contacts for Europe
MC Services AG
Raimund Gabriel
Tel.: +49 (0)89 210 228 0
E-Mail: raimund.gabriel@mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Back to press releases